Dr. Sima Rozati is an Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine. She specializes in medical dermatology, cutaneous lymphoma, and supportive oncodermatology. She received her medical degree from the Shahid Beheshti University of Medical Sciences in Tehran. After completing her internal medicine residency at the Cleveland Clinic, she completed a research fellowship and PhD in cutaneous lymphoma at the University Hospital of Zürich in Switzerland. She returned to the U.S. where she completed cutaneous lymphoma fellowship, under the mentorship of Dr. Youn Kim, followed by dermatology residency at Stanford University School of Medicine in California. In a multidisciplinary environment, Dr. Rozati aims to provide excellent care to patients with cutaneous lymphoma and cancer whom are experiencing cutaneous adverse events from targeted therapies, immune- and chemotherapies. Dr. Rozati’s research interest focuses on cutaneous lymphoma, understanding the biology of this heterogeneous group of malignancies by analyzing the mutational and epigenetic landscape. Her translational research efforts is directed to investigate novel targeted and immunotherapeutic for cutaneous T cell lymphoma. She is a member of different professional organizations, including the American Academy of Dermatology and Woman’s dermatologic Society. Dr. Rozati is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Localized Scleroderma.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Dr. Jihad Mohamad Alhariri is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatology and medical dermatology. Dr. Alhariri received his undergraduate degree from the American University of Beirut. He earned his M.D. from the American University of Beirut and his M.P.H. from the Johns Hopkins University School of Public Health. He completed a residency in internal medicine at Good Samaritan Hospital of Maryland and a residency in dermatology at Johns Hopkins. Dr. Alhariri is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Melanoma, Hidradenitis Suppurativa, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference. Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty. As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation. Dr. Sterling is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

Seung Lee is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Jorge Florindez is an Oncologist in Baltimore, Maryland. Dr. Florindez is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Anaplastic Large Cell Lymphoma, Febrile Neutropenia, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Myringotomy.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

As a member of the Johns Hopkins Kimmel Cancer Center, my group's research is focused on finding novel therapies for the treatment of both acute and chronic graft versus host disease (GVHD). To that end, we are developing new strategies for prophylaxis as well as therapies for this problem. We are exploring the use of drugs such as pentostatin in steroid refractory GVHD. This drug inhibits an enzyme, called ADA, that induces apoptosis (cell death) of lymphocytes, the effector cells in GVHD. Our results using this approach have been quite encouraging. Also, we are exploring other novel approaches such as extracorporeal photopheresis or high-dose cyclophosphamide. We are participating in the NIH Bone Marrow Transplant Clinical Trials Network consortium to find useful therapies for GVHD. We are also members of the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials on Chronic GVHD, and there we are trying to establish rational guidelines for supportive care, trial design, etc. We run an internationally unique GVHD multidisciplinary clinic with many GVHD experts including a nurse practitioner, research nurse and others from fields such as physical medicine and rehabilitation, gastroenterology, ophthalmology, dermatology, pulmonology and more. Dr. Meade is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Multiple Myeloma, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is currently accepting new patients.

Jean Yared is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Yared is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Yared is currently accepting new patients.

Nancy Hardy is an Oncologist and a Transplant Surgeon in Baltimore, Maryland. Dr. Hardy is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. Her top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hardy is currently accepting new patients.

Kathryn Kline is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Kline is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. Her top areas of expertise are Sickle Cell Disease, Waldenstrom Macroglobulinemia, Anaplastic Large Cell Lymphoma, and Acute Myeloid Leukemia (AML). Dr. Kline is currently accepting new patients.

Matthew Ferris is a Radiation Oncologist in Baltimore, Maryland. Dr. Ferris is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. His top areas of expertise are Prostate Cancer, Laryngeal Cancer, Pleuropulmonary Blastoma, Salivary Gland Tumors, and Glossectomy. Dr. Ferris is currently accepting new patients.

Yvette Kasamon is a Hematologist Oncology provider in Baltimore, Maryland. Dr. Kasamon is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. Her top areas of expertise are Graft Versus Host Disease (GvHD), Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Carole Miller is an Oncologist in Baltimore, Maryland. Dr. Miller is rated as an Experienced provider by MediFind in the treatment of Anaplastic Large Cell Lymphoma. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Familial Colorectal Cancer, and Muscle Invasive Bladder Cancer. Dr. Miller is currently accepting new patients.